# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k083463   
B. Purpose for Submission: Device modification (addition of urine matrix)   
C. Measurand: $\beta _ { 2 }$ -microglobulin   
D. Type of Test: Quantitative, immunonephelometry   
E. Applicant: Seimens Healthcare Diagnostics, Inc.   
F. Proprietary and Established Names: Dimension Vista $^ \mathrm { \textregistered }$ B2MIC Flex $^ \mathrm { \textregistered }$ reagent cartridge Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Calibrator Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Control L Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Control M

# G. Regulatory Information:

1. Regulation section: 866.5630 Beta-2-microglobulin immunological test system 862.1150 Calibrator 862.1660 Quality Control Material (Assayed and Unassayed

2. Classification: Class II

3. Product code: JZG System, test, beta-2-microglobulin immunological JIX Calibrator, multi-analyte mixture JJY Multi-analyte controls, all kinds (assayed)

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): Dimension Vista $\textsuperscript { \textregistered }$ B2MIC Flex $\textsuperscript { \textregistered }$ reagent cartridge: The B2MIC method is an in vitro diagnostic test for the quantitative measurement of $\beta _ { 2 }$ -microglobulin in human serum, heparinized plasma, EDTA plasma, and urine using on the Dimension Vista $^ \mathrm { \textregistered }$ Systems. Measurement of $\beta _ { 2 }$ -microglobulin aids in the diagnosis of active rheumatoid arthritis and kidney disease.

Dimension Vista $\textsuperscript { \textregistered }$ Protein 1 Calibrator: PROT1 CAL is an in vitro diagnostic product for the calibration of the Dimension Vista $^ \mathrm { \textregistered }$ Systems for: α1-acid glycoprotein, α1 -antitrypsin, ${ \tt a 2 }$ -macroglobulin, $\beta _ { 2 }$ -microglobulin, C3 complement, C4 complement, ceruloplasmin, haptoglobin, hemopexin, immunoglobulin A, immunoglobulin E, immunoglobulin G, immunoglobulin G subclass 1, immunoglobulin G subclass 2, immunoglobulin G subclass 3, immunoglobulin G subclass 4, immunoglobulin M, prealbumin, retinol binding protein, homocysteine, soluble transferrin receptor and transferrin.

Dimension Vista $\textsuperscript { \textregistered }$ Protein 1 Control L: PROT1 CON L is an assayed, low level, intra-laboratory quality control for assessment of precision and analytical bias on the Dimension Vista $^ \mathrm { \textregistered }$ Systems in the quantitative determination of: α1-acid glycoprotein, ${ \mathfrak { a } } 1$ -antitrypsin, ${ \tt a 2 }$ -macroglobulin, $\beta _ { 2 }$ -microglobulin, C3 complement, C4 complement, ceruloplasmin, haptoglobin, hemopexin, immunoglobulin E, immunoglobulin A, immunoglobulin G, immunoglobulin G Subclass, immunoglobulin G subclass 2, immunoglobulin G subclass 3, immunoglobulin G subclass 4, immunoglobulin M, prealbumin, retinol binding protein, homocysteine, soluble transferrin receptor and transferrin.

Dimension Vista $\textsuperscript { \textregistered }$ Protein 1 Control M: PROT1 CON M is an assayed, midlevel, intra-laboratory quality controls for assessment of precision and analytical bias on the Dimension Vista $^ \mathrm { \textregistered }$ System in the quantitative determination of: α1- acid glycoprotein, α1-antitrypsin, ${ \tt a 2 }$ -macroglobulin, $\beta _ { 2 }$ -microglobulin, C3 complement, C4 complement, ceruloplasmin, haptoglobin, hemopexin, immunoglobulin E, immunoglobulin A, immunoglobulin G, immunoglobulin G Subclass , immunoglobulin G subclass 2, immunoglobulin G subclass 3, immunoglobulin G subclass 4, immunoglobulin M, prealbumin, retinol binding protein, homocysteine, soluble transferrin receptor and transferrin.

2. Indication(s) for use: Same as above.   
3. Special conditions for use statement(s): For prescription use only   
4. Special instrument requirements: Dimension Vista $^ \mathrm { \textregistered }$ System

# I. Device Description:

Dimension Vista $^ \mathrm { \textregistered }$ B2MIC Flex $^ \mathrm { \textregistered }$ reagent cartridge: The cartridge consists of 12 wells capable of providing 100 test results (2 cartridges per carton). All wells contain preservative. Reagent 1 (phosphate buffer, polyethylene glycol sorbitan monolaureate), Reagent 2 (phosphate buffer and immunoglobulin) and a third Reagent consisting of polystyrene particles and monoclonal antibodies to human $\beta _ { 2 }$ - microglobulin. The carton is also supplied with 2 vials of urine stabilizer (polyethylene glycol sorbitan monolaureate solution). Reagents are ready-to-use. Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Calibrator: Protein 1 calibrator is a multi-analyte, liquid human serum based product in a ready-to-use form supplied as 6 vials, $2 . 0 \mathrm { m l }$ per vial.

Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Control L and Protein 1 Control M: Protein 1 Control L and M are multi-analyte, low and mid level, ready-to-use liquid human serum based products. Supplied as 6 vials, $2 . 0 \mathrm { m l }$ per vial.

# J. Substantial Equivalence Information:

1. Predicate device name(s) and 510(k) numbers: N Latex $\beta _ { 2 }$ -microglobulin k002731 N/T Protein Standard SL k052788 N Protein Controls SL k052788

B2MIC Flex $^ \mathrm { \textregistered }$ reagent cartridge   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indications forUse</td><td rowspan=1 colspan=1>For the quantitativemeasurement of β2-microglobulin in human serum,heparinized plasma, EDTAplasma and urine.Measurements of β2-microglobulin aid in thediagnosis of active rheumatoidarthritis and kidney disease.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Immunonephelometry</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum, heparinized plasma, (Li&amp; Na), EDTA plasma, andurine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Mouse monoclonal</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>Liquid and ready for use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>Unopened 2-8°C</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>Dimension Vista Systems</td><td rowspan=1 colspan=1>BN TMSystems</td></tr><tr><td rowspan=1 colspan=1>Reportable range</td><td rowspan=1 colspan=1>0.20 - 5.80 mg/L (0.02 - 0.58mg/dL)</td><td rowspan=1 colspan=1>0.20 - 6.0 mg/L</td></tr><tr><td rowspan=1 colspan=1>Stability: Open well</td><td rowspan=1 colspan=1>21 days at 2-8°C</td><td rowspan=1 colspan=1>4 weeks at 2-8°C</td></tr></table>

# PROT 1 Controls L and M

<table><tr><td colspan="3">Similarities</td></tr><tr><td>Item</td><td>New Device</td><td>Predicate</td></tr><tr><td>Intended Use</td><td>PROT 1 CON L and M are assayed, low level and mid-level intra-laboratory quality control for the assessment of precision and analytical bias</td><td>Same</td></tr><tr><td>Material Source</td><td>Human Serum</td><td>Same</td></tr><tr><td>Reagent Preparation</td><td>Ready-to-Use</td><td>Same</td></tr></table>

<table><tr><td colspan="3">Differences</td></tr><tr><td>Item</td><td>New Device</td><td>Predicate</td></tr><tr><td>Instrument System</td><td>Dimension Vista</td><td>BN Systems</td></tr><tr><td>Analytes</td><td>α1-acid glycoprotein, α1- antitrypsin, α2- macroglobulin, B2- microglobulin, C3</td><td>α1-acid glycoprotein, α1-antitrypsin, α2- macroglobulin, β2 </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">complement, C4complement, ceruloplasmin,haptoglobin, hemopexin,immunoglobulins A, E, Gand M, IgG subclass 1 tosubclass 4, light chainskappa, light chains lambda,prealbumin, retinol bindingprotein, homocysteine,soluble transferrin receptorand transferrin,Immunoglobulin E (IgE)</td><td colspan="1" rowspan="1">microglobulin, C3complement, C4complement,ceruloplasmin,haptoglobin,hemopexin,immunoglobulins A, E,G and M, IgG subclass 1to subclass 4, lightchains kappa, lightchains lambda,prealbumin, retinolbinding protein,transferrin, albumin,soluble transferrinreceptor, ferritin, andtotal protein</td></tr><tr><td colspan="1" rowspan="1">Levels</td><td colspan="1" rowspan="1">Low and Medium</td><td colspan="1" rowspan="1">Low, Medium and High</td></tr><tr><td colspan="1" rowspan="1">Stability; Open</td><td colspan="1" rowspan="1">9 days at 2-8°C</td><td colspan="1" rowspan="1">14 days at 2-8°C</td></tr><tr><td colspan="1" rowspan="1">Quantity</td><td colspan="1" rowspan="1">6 vials, 2.0 mL per vial</td><td colspan="1" rowspan="1">3 vials, 1 mL per vial</td></tr></table>

# PROT1 Calibrator

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>An in vitro diagnostic productfor the calibration of specificanalytes</td><td rowspan=1 colspan=1>Establishment ofreference curves forspecific analytes</td></tr><tr><td rowspan=1 colspan=1>Traceability for TRF-U</td><td rowspan=1 colspan=1>WHO 1st International Standardfor β2-microglobulin</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Liquid human serum based</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>1 level diluted with SystemDiluent to 6 levels. Approximateconcentrations: 0.01, 0.02, 0.04,0.07, 0.15, 0.39 mg/L)</td><td rowspan=1 colspan=1>1 level seriallydiluted</td></tr><tr><td rowspan=1 colspan=1>Reagent Preparation</td><td rowspan=1 colspan=1>Ready-to-Use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability; Open</td><td rowspan=1 colspan=1>14 days at 2-8°C</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8°C</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3">Differences</td></tr><tr><td>Item</td><td>New Device</td><td>Predicate</td></tr><tr><td>Analytes</td><td>α1-acid glycoprotein, α1- antitrypsin, α2-macroglobulin, B2-microglobulin, C3 complement, C4 complement,</td><td>α1-acid glycoprotein, α1-antitrypsin α2- macroglobulin, β2 microglobulin, C3</td></tr><tr><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">ceruloplasmin, haptoglobin,hemopexin, immunoglobulinsA, E, G, and M, IgG subclass 1to subclass 4, light chainskappa, light chains lambda,prealbumin, retinol bindingprotein, homocysteine, solubletransferrin receptor andtransferrin, Immunoglobulin E(IgE).</td><td colspan="1" rowspan="1">complement, C4complement,ceruloplasmin,haptoglobin,hemopexin,immunoglobulins A,E, G and M, IgGsubclass 1 to subclass4, light chains kappa,light chains lambda,prealbumin, retinolbinding protein,transferrin, albumin,soluble transferrinreceptor, ferritin, andtotal protein</td></tr><tr><td colspan="1" rowspan="1">Quantity</td><td colspan="1" rowspan="1">4 vials, 1.0 mL per vial</td><td colspan="1" rowspan="1">3 vials, 1 mL per vial</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staff- Assayed and Unassayed Quality Control Material.

CLSI EP5-A2: Evaluation of Precision Performance in Clinical Chemistry Devices.

CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline.

CLSI EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition.

L. Test Principle:

Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light at $8 4 0 \mathrm { n m }$ is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

# M. Performance Characteristics (if/when applicable):

The performance characteristics for $\beta _ { 2 }$ -microglobulin in serum and plasma are available in the Decision Summary for k063272. The evaluation of $\beta _ { 2 }$ -microglobulin in urine is referred to as the B2MU method below.

# 1. Analytical performance:

a. Precision/Reproducibility: Precision testing for the B2MU method was conducted over twenty days according to CLSI/NCCLS EP5-A2, at a single site. A single instrument, a single reagent lot and a single operator were used. On each day of testing, each sample was run in duplicate in two separate runs. The test samples consisted of two levels of Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Controls, and two pooled urine samples that covered the low and high ends of the measuring range. Analysis of variance (ANOVA) was used to evaluate the data consistent with the recommendations of EP5-A2. The $\%$ CVs for the controls was less than $2 . 3 5 \%$ and the $\%$ CV for the urine pools was less than $6 . 7 \%$ . The data are shown below:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Mean</td><td rowspan=1 colspan=3>Repeatability</td><td rowspan=1 colspan=3>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>mg/dL</td><td rowspan=1 colspan=1>mg/L</td><td rowspan=1 colspan=1>SD mg/dL</td><td rowspan=1 colspan=1>SD mg/L</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD mg/dL</td><td rowspan=1 colspan=1>mg/L</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>PROT1CON L</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>0002</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>1.75</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>2.35</td></tr><tr><td rowspan=1 colspan=1>PROT1CON M</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>1.86</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.036</td><td rowspan=1 colspan=1>1.93</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>2.15</td></tr><tr><td rowspan=1 colspan=1>Urine pool</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.071</td><td rowspan=1 colspan=1>0.71</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>2.92</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>6.66</td></tr><tr><td rowspan=1 colspan=1>Urine pool</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>4.48</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>0.169</td><td rowspan=1 colspan=1>3.78</td><td rowspan=1 colspan=1>0.028</td><td rowspan=1 colspan=1>0.276</td><td rowspan=1 colspan=1>6.15</td></tr></table>

Lot-to-Lot precision was demonstrated using four samples covering the assay range and testing on three reagent lots. Each sample was assayed in triplicate from three different Flex $^ \mathrm { \textregistered }$ cartridges, producing nine replicates per sample for each of the three reagent lots. The mean, standard deviation and $\%$ CV was calculated for the data set of each sample from each lot. The $\%$ CV values were then used to determine the mean $\%$ CV and standard deviation across lots. For each sample, a one sided $9 5 \%$ confidence interval was used to determine the upper limit. The acceptance limit for $\%$ CV for lot-to-lot precision of $< 5 \%$ was met.

# b. Linearity/assay reportable range:

The reportable range for the B2MU method was determined according to CLSI EP-6-A. A high urine sample ${ \left( 5 . 9 5 ~ \mathrm { m g / L } \right) }$ was diluted with System diluent. A urine sample was run neat along with serial dilutions to cover the assay range. A total of 13 levels were prepared and tested. The observed value represents the mean of five replicates. Per the EP6-A procedure, the observed (Y-axis) and expected (X-axis) values were fit by linear and cubic models. Weighted regression fits were used for both models. The same weighting factors were used for each model and were derived from the replicates data by the classical approach of 1/Variance. These models were used to generate predicted values for each sample. The difference between the linear and cubic predicted values for each sample was taken as the bias at each level. The acceptance criteria were defined as: Bias at each level $\leq \pm 0 . 0 5 \mathrm { m g / L }$ or $1 5 \%$ , and the mean bias for all levels $\leq \pm 1 5 \%$ . The range of the bias was -4.98 to $+ 5 . 0 8 \%$ (-0.13 to $+ 0 . 0 5 \mathrm { m g / L } $ ), the mean absolute bias was $2 . 8 \%$ . The acceptance criteria were met. The BSMU analytical measuring range is $0 . 2 0 -$ $5 . 8 0 \mathrm { m g / L } ( 0 . 0 2 - 0 . 5 8 \mathrm { m g / d L } )$ . The first order polynomial is used for the best fitting straight line (linear fit). The regression analysis for the linear fit is as follows: Slope $= 0 . 9 6 5$ Intercept $= 0 . 0 2 9$ . The range of percent recovery at each concentration (observed value/target value) is shown below:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Expectedmg/L</td><td rowspan=1 colspan=1>RecoveryRange(%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>100-107</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>103-106</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>102</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>102-103</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>102-103</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>102-103</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2.51</td><td rowspan=1 colspan=1>102</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3.13</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>3.76</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>4.39</td><td rowspan=1 colspan=1>108-110</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>5.01</td><td rowspan=1 colspan=1>103-104</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>5.64</td><td rowspan=1 colspan=1>102-104</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>6.27</td><td rowspan=1 colspan=1>101-102</td></tr></table>

c. Hook Effect: The possibility of hook effect occurring when using the B2MU assay was evaluated. Testing indicated no hook effect up to $2 4 . 4 \ : \mathrm { m g / d L }$ (244 $\mathrm { { m g / L ) } }$ .

d. Traceability, Stability, Expected values (controls, calibrators): The calibrator and control are traceable to WHO $1 ^ { \mathrm { s t } }$ International Preparation for $\beta _ { 2 }$ -microglobulin.

Stability: Material was tested at day 0, and after 12, 18 and 24 months. Three vials, 3 replicates per vial were tested. For open vial stability, vials were stored on board the instrument and tested in duplicate at 0, 4, 7, 9, 11, 14 days. The acceptance criteria for shelf life $( \pm 1 5 \%$ of the assigned value) and open vial $( \pm 1 0 \%$ of the day 0 value) were met.

Calibrator Expected Values: A typical assigned value for $\beta _ { 2 }$ -microglobulin, in Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Calibrator is $0 . 1 1 6 \mathrm { m g / d L }$ ( $1 . 1 6 \mathrm { m g / L } )$ . Calibration is required for any new lot of reagent or every 30 days for the same lot.

Control Expected Values: A typical analyte concentration for $\beta _ { 2 }$ - microglobulin in Protein 1 Control L is $0 . 1 1 2 \mathrm { m g / d L }$ $\mathrm { 1 . 1 2 \ m g / L ) }$ , and for $\beta _ { 2 }$ - microglobulin in Protein 1 Control M is $0 . 1 8 6 \mathrm { m g / d L }$ $( 1 . 8 6 \mathrm { m g / L } )$ .

e. Detection limit:

Limit of Quantification: Three human urine samples were spiked with the $1 ^ { \mathrm { s t } }$ International Standard for $\beta 2$ -microglobulin concentration of $0 . 1 9 \mathrm { m g / L }$ . Five runs of triplicate determinations on each of three human urine samples were tested on one day with a single reagent and a calibrator lot and instrument. The mean and SD for the 15 replicates for each sample were calculated. The bias for each sample was determined (bias $=$ mean - sample determination). The average bias across the three samples for each concentration was calculated. The pooled SD across the three samples was determined per EP17- A Appendix B. The observed Total Analytical Error (TAE) was calculated. $\mathrm { T A E } =$ average bias plus 2SD) Limit of Quantitation (LoQ) was determined based on the TAE. An acceptance criterion of $30 \%$ was used based on precision and recovery performance of the method. The Limit of Quantitation for $\beta _ { 2 } .$ - microglobulin in urine was determined to be $0 . 0 1 9 \mathrm { m g / d L }$ $( 0 . 1 9 \mathrm { m g / L } )$ .

# f. Analytical specificity:

Interference testing was conducted in accordance with CLSI EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition. Test samples were prepared by spiking the potential interferent into urine. Ten replicates of each urine sample with interferent were tested. Control samples for ß2-microglobulin in the urine samples tested ranged from $0 . 0 2 2 ~ \mathrm { m g / d L } - 0 . 4 9 5 \mathrm { m g / d L }$ $( 0 . 2 2 \mathrm { m g / L } - 4 . 9 5 \mathrm { m g / L } )$ . The recovery of ß2- microglobulin in the presence of spiked material ranged from $9 0 - 1 0 3 \%$ . The acceptance criterion for the bias (less than $\pm 1 0 \%$ ) was met in all cases.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Concentrationspiked</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>750mg/dL</td></tr><tr><td rowspan=1 colspan=1>Boric acid</td><td rowspan=1 colspan=1>800mg/dL</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>500mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1000mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>2000mg/dL</td></tr><tr><td rowspan=1 colspan=1>Human serum albumin</td><td rowspan=1 colspan=1>500mg/dL</td></tr><tr><td rowspan=1 colspan=1>Immunoglobulin G(IgG)</td><td rowspan=1 colspan=1>500mg/dL</td></tr><tr><td rowspan=1 colspan=1>Oxalic acid</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>7.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Sodium azide</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Sodiumchloride</td><td rowspan=1 colspan=1>6000mg/dL</td></tr><tr><td rowspan=1 colspan=1>Sodiumfluoride</td><td rowspan=1 colspan=1>900mg/dL</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>4000mg/dL</td></tr></table>

g. Assay cut-off:

The concentration of $\beta 2$ -microglobulin in urine of healthy individuals is below the detection limit of detection for this method (less than $0 . 0 2 0 \mathrm { m g / d L }$ $[ 0 . 2 0 \mathrm { m g / L } ] )$ . Samples with less than $0 . 0 2 \mathrm { m g / d L }$ $( 0 . 2 0 \mathrm { m g / L } )$ are reported as “less than $0 . 0 2 \mathrm { m g / d L } ^ { \mathrm { \prime } }$ by the instrument.

2. Comparison studies:

a. Method comparison with predicate device: Performance between the Dimension Vista $^ \mathrm { \textregistered }$ B2MIC Flex $^ \mathrm { \textregistered }$ reagent cartridge and the predicate was compared. The study included 42 native specimens, with $\beta _ { 2 }$ -microglobulin ranging from $0 . 0 2 2 \mathrm { ~ - ~ } 0 . 5 5 \mathrm { m g / d L }$ $( 0 . 2 2 - 5 . 5 2 \mathrm { m g / L ) }$ , and 40 spiked specimens. Spiked samples were prepared by adding purified $\beta _ { 2 }$ -microglobulin to individual specimens. An additional 27 samples were run for the extended high range. Passing-Bablock regression yielded the following statistics:

<table><tr><td>Comparative Method</td><td>Sample range (mg/L)</td><td>Slope (mg/L) 95%C)</td><td>Y-Intercept (mg/L) (95%CI)</td><td>Correlation Coefficient (r2)</td><td>n</td></tr><tr><td rowspan="2">N Latex β2- microglobulin on the BN ProSpec System</td><td>0.22 - 5.52</td><td>0.952 (0.926 to 0.972)</td><td>0.008 (-0.023 to 0.018)</td><td>0.975</td><td>82</td></tr><tr><td>9.26 - 21.0</td><td>0.971 (0.866 to 1.089)</td><td>0.653 (-0.603 to 1.807)</td><td>0.907</td><td>33</td></tr></table>

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity and Specificity: Not applicable.   
b. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Same as assay cut-off.

5. Expected values/Reference range:

The concentration of $\beta 2$ -microglobulin in urine of healthy individuals is below the detection limit of detection for this method (less than $0 . 0 2 0 \mathrm { m g / d L }$ $[ 0 . 2 0 \mathrm { m g / L } ]$ ). This reference interval is based on Lammers M, Gentzler W., Reifferscheidt G, Schmidt B. Determination of Beta 2 microglobulin by a particle enhanced immunonephelometric assay. Clin Chem 2002; 48: A-119. The reference interval was confirmed by running a transference study as outlined in CLSI C28-A2 How to Define and Determine Reference Intervals in the Clinical Laboratory - Second Edition. The acceptance criterion was defined that no more than $10 \%$ of the values could lie outside the published range of $< 0 . 0 2 \mathrm { m g / d L }$ . The acceptance criterion was met as all samples fell within the published range.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.